Aaron Seth Kesselheim

Aaron Seth Kesselheim, MD, JD, MPH

Professor of Medicine
Member, HMS Center for Bioethics

Aaron S. Kesselheim, MD, JD, MPH, is a Professor of Medicine at Harvard Medical School and a faculty member in the Division of Pharmacoepidemiology and Pharmacoeconomics in the Department of Medicine at Brigham and Women’s Hospital. Within the Division, Aaron created and leads the Program On Regulation, Therapeutics, And Law (PORTAL, www.PORTALresearch.org), an interdisciplinary research core focusing on intersections among prescription drugs and medical devices, patient health outcomes, and regulatory practices and the law. PORTAL is now among the largest, independent academic centers focusing on these issues in the country (Twitter: @PORTAL_research, @akesselheim). Dr. Kesselheim received his medical and legal training at the University of Pennsylvania and his M.P.H. at the Harvard School of Public Health. Author of over 450 publications in the peer-reviewed medical and health policy literatures, Aaron has testified before Congress on pharmaceutical policy, medical device regulation, generic drugs, and modernizing clinical trials, is a member of the FDA Peripheral and Central Nervous System Advisory Committee, and served on a National Academies of Science, Engineering and Medicine consensus committees on addressing the opioid epidemic and bioidentical hormone replacement. At the HMS Center for Bioethics, he co-teaches a course on health policy, law, and bioethics and organizes the monthly policy and ethics consortium.

Publications View
Association of the Priority Review Voucher With Neglected Tropical Disease Drug and Vaccine Development.
Authors: Authors: Jain N, Hwang T, Franklin JM, Kesselheim AS.
JAMA
View full abstract on Pubmed
Coverage of Magnetic Resonance Imaging for Patients With Cardiac Devices: Improving the Coverage With Evidence Development Program.
Authors: Authors: Kramer DB, Kesselheim AS.
JAMA Cardiol
View full abstract on Pubmed
Do patients trust the FDA?: a survey assessing how patients view the generic drug approval process.
Authors: Authors: Kesselheim AS, Gagne JJ, Franklin JM, Eddings W, Fulchino LA, Campbell EG.
Pharmacoepidemiol Drug Saf
View full abstract on Pubmed
Changes in prescribing and healthcare resource utilization after FDA Drug Safety Communications involving zolpidem-containing medications.
Authors: Authors: Kesselheim AS, Donneyong M, Dal Pan GJ, Zhou EH, Avorn J, Schneeweiss S, Seeger JD.
Pharmacoepidemiol Drug Saf
View full abstract on Pubmed
The Effects of the Sunshine Act: What Can and Should We Expect?
Authors: Authors: Sinha MS, Kesselheim AS.
Am J Bioeth
View full abstract on Pubmed
Journey of Generic Imatinib: A Case Study in Oncology Drug Pricing.
Authors: Authors: Chen CT, Kesselheim AS.
J Oncol Pract
View full abstract on Pubmed
Patient and Physician Perceptions of Drug Safety Information for Sleep Aids: A Qualitative Study.
Authors: Authors: Kesselheim AS, McGraw SA, Dejene SZ, Rausch P, Dal Pan GJ, Lappin BM, Zhou EH, Avorn J, Campbell EG.
Drug Saf
View full abstract on Pubmed
Success, Failure, and Transparency in Biomarker-Based Drug Development: A Case Study of Cholesteryl Ester Transfer Protein Inhibitors.
Authors: Authors: Hey SP, Franklin JM, Avorn J, Kesselheim AS.
Circ Cardiovasc Qual Outcomes
View full abstract on Pubmed
Accelerated Approval and Expensive Drugs - A Challenging Combination.
Authors: Authors: Gellad WF, Kesselheim AS.
N Engl J Med
View full abstract on Pubmed
FDA Approval of Desmopressin for Nocturia.
Authors: Authors: Fralick M, Kesselheim AS.
JAMA
View full abstract on Pubmed

Address: 
Brigham and Women's Hospital
Boston, MA 02120